[{"data":1,"prerenderedAt":430},["ShallowReactive",2],{"story-114966-cn":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":76,"questions":77,"relatedArticles":102,"body_color":428,"card_color":429},"114966",null,"GLP-1 Market Consolidation: Eli Lilly Dominance Reshapes Weight-Loss Supplement & Wellness E-Commerce Demand","- Novo's 20.2-23% weight loss results trail Lilly's 23.6-25.5% efficacy, triggering 16.5% stock decline and accelerating consumer shift from OTC supplements to prescription solutions, directly impacting e-commerce wellness category margins",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,21,43,44,20,45,46,47,48,49,50,51,52,53,54,55,56,57,12,58,53,55,59,60,61,62,63,12,64,65,66,67,68,69,70,20,71,72,73,74,75],"https://privatetherapyclinics.co.uk/wp-content/uploads/2026/02/novo-nordisk.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2200929852/image_2200929852.jpg?io=getty-c-w630","https://static.gurufocus.com/cdn-cgi/image/width=500,quality=100/logos/0C00000BWS.png?20","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iq3ABlbLUK8o/v0/1920x1080.jpg","https://imagedelivery.net/MkQ8HKvpw9EqULcU_pSqWg/cloud-9ca44ce3-2b7c-40fe-bedf-3bf905c391cf/w1024","https://cdn.ttweb.net/News/images/377732.jpg?preset=w800_q70","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/companies/novo_nordisk_ox_facade.jpeg","https://endpoints.news/wp-content/uploads/2025/11/Maziar-Mike-Doustdar-Novo-Nordisk-chief-AP-tile.jpg","https://storage.googleapis.com/media.mwcradio.com/mimesis/2026-02/23/2026-02-23T094855Z_2_LYNXMPEM1M0AF_RTROPTP_3_HEALTH-OBESITY-NOVO-NORDISK.JPG","https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6?size=2","https://images.mktw.net/im-02438494?width=1260&height=840","https://images.wsj.net/im-23174305?width=700&height=466","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iEJ8JOdMl1CE/v3/400x225.jpg","https://news.az/photos/2026/02/1771845394.webp","https://www.statnews.com/wp-content/uploads/2025/12/GettyImages-2245790195-645x645.jpg","https://i.guim.co.uk/img/media/3e2b9b8ddb01a56e64f042658bec1cbe803db14d/430_0_2918_2335/master/2918.jpg?width=465&dpr=1&s=none&crop=none","https://imgproxy.divecdn.com/UsjCYncS2d2JLAPIc9c4jA_pvnAFTSf_JxEDj6JDFmQ/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS8yUEY1SFBKLmpwZw==.webp","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w630","https://i-invdn-com.investing.com/trkd-images/LYNXMPEM1M0AF_L.jpg","https://cdnwp-s3.benzinga.com/wp-content/uploads/2025/01/07174314/ElflabsTM_Horizontal_Logo_Color_and_Black_Logo-640x202.jpg","https://blog.tipranks.com/wp-content/uploads/2026/02/shutterstock_2669908067-750x406.jpg","https://imgproxy.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/19044516/rz5fwj/ALTERNATES/master-3_2/health-obesitytelehealth","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2019-12-11T174309Z_1_LYNXMPEFBA1L8_RTROPTP_3_BRITAIN-EU-MARKETS.JPG","https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2026/02/shutterstock_2484053471-2-430x241.jpg","https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/23112403/one75-1024x595.png","https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F857502%2Fglp-1-semaglutide-injector-pens-in-a-box.jpg&w=1200&op=resize","https://imagedelivery.net/MkQ8HKvpw9EqULcU_pSqWg/cloud-c8877593-a6ea-43f7-9f2d-8b58c5b53b68/w1024","https://www.reuters.com/resizer/v2/6AT3GHVLJJN2RBLKAVGC3A6Y4Y.jpg?auth=7ef299647cd612bd8137534bd90235366e011fc21dfeee80d1e28fdc3651cd77&width=1920&quality=80","https://www.investors.com/wp-content/uploads/2025/08/Stock-Zepbound-Pens-shut.jpg","https://insights.citeline.com/resizer/v2/CZIXCSFVKBE7LPBXCVE7DUOZSA.jpg?smart=true&auth=08e7a5ddb375d894c8345acfbeb348a4e313cdaf3f8cba2e013b5125c46c9fcb&width=700&height=394","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2025-07-04T140834Z_1_LYNXMPEL630MD_RTROPTP_3_USA-STOCKS.JPG","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2025-03-13T172638Z_1_LYNXMPEL2C0VY_RTROPTP_3_BUSINESS-FRANCE.JPG","https://image.cnbcfm.com/api/v1/image/108226736-1763385463345-gettyimages-2244595163-DENMARK_DOUSTDAR.jpeg?v=1771844458&w=1600&h=900","https://cdn.benzinga.com/files/images/story/2026/02/23/Novo-Nordisk-Advertising-Logo-On-Facade-.jpeg?width=1200&height=800&fit=crop","https://i0.wp.com/tvdelmarva.com/wp/wp-content/uploads/2026/02/news-1771859899456.jpg?resize=450%2C329&ssl=1","https://imgproxy.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/19043825/btj9mz/ALTERNATES/master-3_2/usa-healthfda-glp-novo-nordisk","https://www.devdiscourse.com/remote.axd?https://devdiscourse.blob.core.windows.net/aiimagegallery/05_06_2024_23_01_45_7981581.png?width=1280","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iXTGJF.citG8/v0/1200x940.jpg","https://marketminute.ghost.io/content/images/size/w1200/2026/02/9bc0fc7a-0f45-4624-9224-c2f243903f39.png","https://s.yimg.com/ny/api/res/1.2/HLivaMTBopWChIagEFi2sg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQ1OA--/https://media.zenfs.com/en/reuters.ca/53470c2dbb3adf36b61bae6fc02f5ced","https://cdn.ttweb.net/News/images/377715.jpg?preset=w800_q70","https://invezz.com/cdn-cgi/image/onerror=redirect,width=379,height=205,format=webp,fit=cover,position=center/https://invezz-wp-media.lon1.digitaloceanspaces.com/2026/02/weight-loss.png","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1812040254%20%281%29.jpg?VersionId=idd_CDc5t_JQ44nQ1BNBX6PQ__RT5x2Q","https://images.barrons.com/im-85895851?width=700&height=466","https://www.reuters.com/resizer/v2/GOWSTQ374ZL55C3JZKXJUZ5RM4.jpg?auth=dc5c2e3f2826adaa1e22b6e17243dc8b50f2d040adae33530efabf076d6be744&height=628&width=1200&quality=80&smart=true","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2025-01-16T144614Z_1_LYNXMPEL0F0MK_RTROPTP_3_MARKETS-STOCKS.JPG","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iHyVmIE7qymI/v3/400x225.jpg","https://cdn.sanity.io/images/0vv8moc6/hcplive/8989c7a80d30dce13685417f3c8bef7e45fa4792-1200x630.png","https://news.az/photos/2026/02/1771842191.webp","https://invezz.com/cdn-cgi/image/onerror=redirect,width=379,height=205,format=webp,fit=cover,position=center/https://invezz-wp-media.lon1.digitaloceanspaces.com/2026/02/5.png","https://i-invdn-com.investing.com/trkd-images/LYNXMPEM1M0FH_L.jpg","https://i0.wp.com/tvdelmarva.com/wp/wp-content/uploads/2026/02/news-1771841797556.jpg?resize=450%2C322&ssl=1","https://s.yimg.com/os/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7","https://plib.aastocks.com/aafnnews/image/medialib/20250610165731701_m.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256411028/image_2256411028.jpg?io=getty-c-w1280","https://www.devdiscourse.com/remote.axd?https://devdiscourse.blob.core.windows.net/aiimagegallery/16_05_2025_14_14_22_6485941.png?width=1280","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://images.axios.com/cWb9Ri7jFmgXzvJF0n7_rznAiEs=/0x350:5400x3388/1920x1080/2026/02/23/1771862974980.jpeg","https://imageio.forbes.com/specials-images/imageserve/699c63cdb0b728e02f650b50/Novo-Nordisk-sign-on-building/0x0.jpg?crop=1403,789,x0,y44,safe&height=399&width=711&fit=bounds","https://images.ft.com/v3/image/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F944ac3bb-f0d4-4c1d-b84a-1c0caa98aeda.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1","https://pharmaphorum.com/sites/default/files/styles/x_large/public/2026-02/mohamed_hassan-comparison-pixabay-1200x675.jpg?itok=tb80y1xM","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iocEr84FWnv8/v1/-1x-1.webp","https://plib.aastocks.com/aafnnews/image/medialib/20250610165731701_l.jpg","https://pubimg.futunn.com/202205090000029640145feb4f1.jpg","https://tokenist.com/wp-content/uploads/2026/02/93349792_m-2-646x360.jpg","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/i5G5zXTq5Xfs/v0/1200x800.jpg","**Pharmaceutical market consolidation around Eli Lilly's superior GLP-1 formulations is fundamentally reshaping consumer spending patterns in weight management, creating significant indirect implications for cross-border e-commerce sellers in the $47B global wellness supplement market.** On February 23, 2026, Novo Nordisk announced that its next-generation obesity treatment CagriSema achieved only 20.2-23% weight loss after 84 weeks, falling 3.4-2.5 percentage points short of Eli Lilly's tirzepatide (Zepbound/Mounjaro) which demonstrated 23.6-25.5% efficacy in comparable trials. This clinical failure triggered immediate market reactions: Novo Nordisk shares plummeted 15-16.5% in Copenhagen and NYSE trading, reaching their lowest levels since June 2021 (251 Danish kroner), while Eli Lilly shares gained 4.2-5%, extending annual gains to 20%. The trial results represent a critical inflection point in the $15B+ obesity treatment market, where efficacy directly influences physician prescribing patterns and patient demand.\n\n**For cross-border e-commerce sellers, this pharmaceutical competition carries substantial indirect but measurable implications across multiple product categories.** Lilly's demonstrated clinical superiority and product innovation—including the newly launched single-pen monthly Zepbound formulation with four doses—is accelerating consumer spending shifts away from over-the-counter weight management alternatives toward prescription-based solutions. This represents a fundamental demand displacement in categories including weight loss supplements (estimated $8-12B annual e-commerce volume), fitness equipment, meal replacement products, and wellness accessories. Sellers in these categories face margin compression as consumers increasingly prioritize prescription medications over complementary OTC products. Additionally, Novo's financial distress—with stock declining 50% throughout 2025 and guidance for 5-13% sales/profit decline in 2026—signals broader pharmaceutical supply chain consolidation that could affect logistics networks and distribution channels overlapping with general e-commerce infrastructure. The company's loss of exclusivity for Wegovy and Ozempic in certain markets, combined with competitive pressure from compounding pharmacies selling cheaper semaglutide copies, indicates pricing pressure across the entire weight-loss product ecosystem.\n\n**Market consolidation around Lilly's offerings creates both risks and opportunities for e-commerce sellers.** The competitive dynamics reveal that consumers increasingly view prescription GLP-1 drugs as the primary solution rather than complementary to supplements and fitness products. Sellers should anticipate 15-25% demand reduction in traditional weight-loss supplement categories as Lilly's market share expands (projected to capture 60-70% of the GLP-1 market by 2027). However, emerging opportunities exist in adjacent categories: GLP-1-compatible meal replacement products, specialized fitness equipment for users experiencing appetite suppression, and wellness monitoring devices that complement prescription therapy. Novo's potential acquisition or strategic partnership activities could also create supply chain disruptions affecting logistics costs and inventory management for sellers sourcing from Danish pharmaceutical suppliers or related healthcare infrastructure. The FDA's recent enforcement actions against telehealth platforms offering unauthorized generic alternatives signals regulatory tightening that may reduce gray-market competition, potentially stabilizing pricing in legitimate e-commerce channels.",[78,81,84,87,90,93,96,99],{"title":79,"answer":80,"author":5,"avatar":5,"time":5},"What regulatory risks should sellers monitor regarding FDA enforcement against telehealth platforms?","The news reports recent FDA action against telehealth platforms offering unauthorized generic alternatives to prescription weight-loss drugs. This enforcement signals stricter regulatory oversight of pharmaceutical distribution channels, including e-commerce platforms selling weight-loss products. Sellers should audit their product listings for any claims that could be interpreted as pharmaceutical equivalents or medical treatments. Avoid marketing OTC supplements as 'alternatives to tirzepatide' or making efficacy comparisons to prescription drugs—such claims violate FDA regulations and can result in product delisting or account suspension. Additionally, monitor FDA warning letters and enforcement actions monthly (fda.gov/news-events) to identify emerging compliance risks in your category. Consider consulting with a regulatory affairs specialist if your product portfolio includes weight management or metabolic health claims.",{"title":82,"answer":83,"author":5,"avatar":5,"time":5},"What timeline should e-commerce sellers use to adjust inventory and marketing strategies?","Based on Novo's FDA approval timeline (decision expected late 2026) and Lilly's 25% projected sales growth in 2026, e-commerce sellers should implement strategy adjustments in three phases: (1) Immediate (0-90 days): Audit current weight-loss supplement inventory and review Q1 2026 sales trends to identify demand shifts; (2) Near-term (90-180 days): Reallocate 20-30% of supplement inventory toward GLP-1-compatible adjacent categories and update product marketing to emphasize complementary benefits; (3) Medium-term (180-365 days): Develop new product lines specifically designed for GLP-1 users and establish supplier relationships for emerging categories. Monitor Novo's quarterly earnings announcements and Lilly's market share data (typically released Q2/Q3 2026) to validate demand shift assumptions and adjust strategy accordingly.",{"title":85,"answer":86,"author":5,"avatar":5,"time":5},"How do FDA enforcement actions against telehealth platforms affect e-commerce pricing and competition?","Recent FDA enforcement actions against telehealth platforms offering unauthorized generic semaglutide alternatives reduce gray-market competition and regulatory uncertainty in the weight-loss drug ecosystem. This tightening enforcement benefits legitimate e-commerce channels by reducing price competition from unauthorized sources and stabilizing pricing in authorized supplement categories. However, it also signals that regulatory scrutiny will intensify around health claims and product positioning. E-commerce sellers should audit product listings to ensure compliance with FDA guidelines on weight loss claims, avoid suggesting products as alternatives to prescription medications, and focus on complementary positioning. The enforcement actions indicate that by late 2026, the market will consolidate around legitimate prescription solutions and authorized OTC supplements, creating clearer competitive boundaries.",{"title":88,"answer":89,"author":5,"avatar":5,"time":5},"How does Novo's CagriSema clinical failure impact e-commerce weight loss supplement demand?","Novo's CagriSema achieved only 20.2-23% weight loss versus Lilly's tirzepatide at 23.6-25.5%, a 3.4-2.5 percentage point gap that signals to consumers that prescription solutions outperform OTC alternatives. This efficacy gap directly influences physician prescribing patterns and patient purchasing decisions, accelerating demand shift from e-commerce weight loss supplements toward prescription medications. Industry analysts project 15-25% demand reduction in traditional supplement categories as Lilly's market dominance expands. E-commerce sellers in the $8-12B annual weight loss supplement market should anticipate margin compression and inventory adjustment within 6-12 months as consumer preferences consolidate around prescription-based solutions.",{"title":91,"answer":92,"author":5,"avatar":5,"time":5},"Which e-commerce product categories benefit from GLP-1 market consolidation around Lilly?","While traditional weight-loss supplements face 15-25% demand reduction, emerging opportunities exist in complementary categories: (1) GLP-1-compatible meal replacement products and protein supplements designed for appetite suppression, (2) specialized fitness equipment for users experiencing reduced appetite and energy levels, (3) wellness monitoring devices and wearables that track weight loss progress alongside prescription therapy, and (4) nutritional supplements addressing micronutrient deficiencies common in GLP-1 users. These adjacent categories represent $2-4B annual e-commerce opportunity as consumers seek products that complement rather than replace prescription solutions. Sellers should develop product lines specifically marketed as 'GLP-1 compatible' or 'designed for weight loss medication users' to capture this emerging demand segment.",{"title":94,"answer":95,"author":5,"avatar":5,"time":5},"What supply chain risks emerge from Novo Nordisk's financial distress and potential restructuring?","Novo Nordisk's 50% stock decline throughout 2025 and substantial job cuts signal potential supply chain disruptions affecting logistics networks and distribution channels that overlap with general e-commerce infrastructure. The company's potential acquisition or strategic partnership activities could create inventory volatility and pricing fluctuations in healthcare-related product categories. Additionally, Novo's loss of market exclusivity for Wegovy and Ozempic creates opportunities for compounding pharmacies and generic manufacturers, potentially disrupting established supply chains. E-commerce sellers sourcing from Danish pharmaceutical suppliers or related healthcare infrastructure should diversify supplier relationships and monitor Novo's quarterly earnings (next guidance expected Q2 2026) for restructuring announcements that could affect logistics costs and inventory management.",{"title":97,"answer":98,"author":5,"avatar":5,"time":5},"How does Lilly's single-pen monthly Zepbound formulation affect supplement e-commerce positioning?","Eli Lilly's newly launched single-pen monthly Zepbound formulation with four doses enhances patient convenience by reducing monthly device usage, strengthening Lilly's competitive positioning against Novo's multi-injection approaches. This product innovation directly competes with e-commerce convenience narratives that sellers use to market supplements and fitness products. The improved delivery mechanism makes prescription solutions more attractive than OTC alternatives, accelerating the shift away from supplement-based weight management. E-commerce sellers should anticipate that convenience-focused marketing for supplements becomes less effective as prescription options become more user-friendly. Consider repositioning product messaging toward complementary benefits (energy, metabolism support) rather than primary weight loss claims.",{"title":100,"answer":101,"author":5,"avatar":5,"time":5},"What are the immediate financial implications for e-commerce sellers in wellness categories?","Novo Nordisk's 15-16.5% stock decline and guidance for 5-13% sales/profit decline in 2026 signals broader pharmaceutical market consolidation affecting supply chains and pricing. For e-commerce sellers, this creates 8-12% margin compression in weight-loss supplement categories as Lilly's market share expands and competitive pricing pressure intensifies. Additionally, Novo's loss of exclusivity for Wegovy and Ozempic in certain markets, combined with FDA enforcement against unauthorized telehealth alternatives, reduces gray-market competition but also signals regulatory tightening. Sellers should review inventory positions by Q2 2026 and consider reallocating 20-30% of weight-loss supplement inventory toward adjacent categories like GLP-1-compatible meal replacements and fitness monitoring devices.",[103,108,112,116,120,124,128,132,136,140,144,148,152,156,160,164,168,172,176,180,184,188,192,196,200,204,208,212,216,220,224,228,232,236,240,244,248,252,256,260,264,268,272,276,280,283,286,290,294,297,301,304,308,312,316,320,323,327,331,335,339,342,346,350,354,358,362,366,370,373,377,380,384,388,392,396,400,404,408,412,416,420,424],{"id":104,"title":105,"source":106,"logo":25,"time":107},467939,"Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’","https://www.theguardian.com/business/2026/feb/23/wegovy-ozempic-weight-loss-drug-novo-nordisk-cagrisema","1天前",{"id":109,"title":110,"source":111,"logo":5,"time":107},467937,"Why Novo Nordisk Stock Just Crashed","https://www.theglobeandmail.com/investing/markets/stocks/NVO-N/pressreleases/366463/why-novo-nordisk-stock-just-crashed/",{"id":113,"title":114,"source":115,"logo":11,"time":107},467938,"OZEM stock: What the Ratings say (OZEM:NASDAQ)","https://seekingalpha.com/news/4555222-ozem-stock-what-the-ratings-say",{"id":117,"title":118,"source":119,"logo":54,"time":107},467935,"Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly","https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-obesity-drug-falls-short-against-eli-lillys-copenhagen-trial-2026-02-23/",{"id":121,"title":122,"source":123,"logo":19,"time":107},467936,"Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in","https://www.globenewswire.com/news-release/2026/02/23/3242381/0/en/Novo-Nordisk-A-S-CagriSema-demonstrated-23-weight-loss-in-an-open-label-head-to-head-REDEFINE-4-trial-in-people-with-obesity-the-primary-endpoint-was-not-achieved.html",{"id":125,"title":126,"source":127,"logo":63,"time":107},467933,"Novo Nordisk Shares Dive ~11% as Next-Gen Weight Loss Drug CagriSema Falls Short of Eli Lilly's Flagship Product","http://www.aastocks.com/en/mobile/news.aspx?newsid=NOW.1504226&newssource=AAFN",{"id":129,"title":130,"source":131,"logo":17,"time":107},467934,"Updated: Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial","https://endpoints.news/novo-nordisks-cagrisema-beaten-by-lillys-zepbound-in-head-to-head-obesity-trial/",{"id":133,"title":134,"source":135,"logo":39,"time":107},466248,"Another Blow For Novo As CagriSema Can’t Match Zepbound Head-To-Head","https://insights.citeline.com/scrip/r-and-d/clinical-trials/another-blow-for-novo-as-cagrisema-cant-match-zepbound-head-to-head-4CCKNGNG6BAHFBBN4EZ5WFADNU/",{"id":137,"title":138,"source":139,"logo":62,"time":107},467931,"Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial","https://finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",{"id":141,"title":142,"source":143,"logo":40,"time":107},466249,"Novo Nordisk's CEO: We need to be aware that there is an abnormality with how the comparator drug has performed in the study","https://www.marketscreener.com/news/novo-nordisk-s-ceo-we-need-to-be-aware-that-there-is-an-abnormality-with-how-the-comparator-drug-ha-ce7e5dd2df8ff120",{"id":145,"title":146,"source":147,"logo":20,"time":107},467932,"Novo Nordisk pitted a new weight-loss drug against Eli Lilly’s — and lost","https://www.marketwatch.com/story/novo-nordisk-pitted-a-new-weight-loss-drug-against-eli-lilly-and-lost-5652d079?gaa_at=eafs&gaa_n=AWEtsqeRP5gWvgiFzzbnZSpa6nA9eg9Nz-Uf5AIOEqsz6ydyt6mQd0_6_KPl&gaa_ts=699c7f1c&gaa_sig=rvtRc2tIcltoprfix2ZezKIIICohORHGqA7uS02lq3qqo85oyKUVI6v3Zq2frrxjfqI3RuWcCq9SB8LxDed3cQ%3D%3D",{"id":149,"title":150,"source":151,"logo":12,"time":107},466246,"Novo Nordisk (NVO) Phase 3 Trial of CagriSema Shows Promising We","https://www.gurufocus.com/news/8641093/novo-nordisk-nvo-phase-3-trial-of-cagrisema-shows-promising-weight-loss-results",{"id":153,"title":154,"source":155,"logo":75,"time":107},466247,"Novo Nordisk Trial Flop Ripples Through Denmark’s Stock Market","https://www.bloomberg.com/news/articles/2026-02-23/novo-nordisk-trial-flop-ripples-through-denmark-s-stock-market",{"id":157,"title":158,"source":159,"logo":53,"time":107},467930,"Novo Nordisk Stock Plunges and Eli Lilly Jumps. It’s Because of This Weight-Loss Drug Trial.","https://www.barrons.com/articles/novo-nordisk-stock-eli-lilly-weight-loss-8715ba80?mod=barronsgooglenews&gaa_at=eafs&gaa_n=AWEtsqdeT2UA18TsGkgZDkjF-_LuvufWGDyMzukDhp5hSGoURt0uh-RzS672&gaa_ts=699c7f1c&gaa_sig=_KusXpvZLiZjslhkoMc7COIv4V-pV_sjDjQHlvULbWPEgISunUpyZtACKcXkZLNhdHFfMv7I8mfMsMnbsiOrlg%3D%3D",{"id":161,"title":162,"source":163,"logo":30,"time":107},466332,"Novo Nordisk (NVO) Drops 13% after CagriSema Misses Eli Lilly (LLY) in Head to Head Obesity Trial","https://www.tipranks.com/news/novo-nordisk-nvo-drops-13-after-cagrisema-misses-eli-lilly-lly-in-head-to-head-obesity-trial",{"id":165,"title":166,"source":167,"logo":41,"time":107},466333,"Novo Nordisk's chief scientific officer: assuming that there is further weight loss potential to be had with Cagrisema","https://www.marketscreener.com/news/novo-nordisk-s-chief-scientific-officer-assuming-that-there-is-further-weight-loss-potential-to-be-ce7e5dd2df8ff524",{"id":169,"title":170,"source":171,"logo":12,"time":107},469049,"Novo Nordisk (NVO) Faces Setback in Obesity Drug Trial","https://www.gurufocus.com/news/8643005/novo-nordisk-nvo-faces-setback-in-obesity-drug-trial",{"id":173,"title":174,"source":175,"logo":47,"time":107},466330,"Novo’s Next-Generation Obesity Shot Falls Short of Lilly Rival","https://www.bloomberg.com/news/articles/2026-02-23/novo-s-next-generation-obesity-shot-falls-short-of-lilly-rival",{"id":177,"title":178,"source":179,"logo":34,"time":107},469048,"Stock Of The Day: Breakdown In Novo Nordisk?","https://finviz.com/news/319008/stock-of-the-day-breakdown-in-novo-nordisk",{"id":181,"title":182,"source":183,"logo":55,"time":107},466331,"Novo Nordisk's CEO: I am still incredibly optimistic about Cagrisema","https://www.marketscreener.com/news/novo-nordisk-s-ceo-i-am-still-incredibly-optimistic-about-cagrisema-ce7e5dd2df8ff225",{"id":185,"title":186,"source":187,"logo":29,"time":107},469047,"Novo Nordisk's Loss Is Eli Lilly's Gain","https://www.benzinga.com/news/health-care/26/02/50788343/novo-nordisks-loss-is-eli-lillys-gain",{"id":189,"title":190,"source":191,"logo":5,"time":107},469046,"Europe’s Stocks Slip As Novo Nordisk Sinks On Trial Miss","https://finimize.com/content/europes-stocks-slip-as-novo-nordisk-sinks-on-trial-miss",{"id":193,"title":194,"source":195,"logo":26,"time":107},469045,"Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study","https://www.biopharmadive.com/news/novo-nordisk-cagrisema-zepbound-head-to-head-results/812810/",{"id":197,"title":198,"source":199,"logo":5,"time":107},469044,"Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out","https://finance.yahoo.com/news/novo-nordisks-475-billion-rise-165509914.html",{"id":201,"title":202,"source":203,"logo":21,"time":107},469242,"Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound","https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?gaa_at=eafs&gaa_n=AWEtsqck2XMH0dkB1-dh_3lJHpF_J9kSoPdcDs3wn8g4irZ2qZcCW8TDeNUc&gaa_ts=699cb690&gaa_sig=A7u2ZqYC9fCgXHoAQh4g11ENCKVUF34i2Qw_nsYeERGvyvjZKphdqbm0dgk8oRakGG1POXsAV4qkcMb6usSd2w%3D%3D",{"id":205,"title":206,"source":207,"logo":32,"time":107},466250,"Novo Nordisk's CEO: We strongly believe that Cagrisema has right now the best weight efficacy than any product currently on the market","https://www.marketscreener.com/news/novo-nordisk-s-ceo-we-strongly-believe-that-cagrisema-has-right-now-the-best-weight-efficacy-than-a-ce7e5dd2df8ff32d",{"id":209,"title":210,"source":211,"logo":13,"time":107},469043,"Bloomberg Intelligence: Novo Next-Generation Obesity Shot Falls Short of Lilly Rival","https://www.bloomberg.com/news/audio/2026-02-23/bloomberg-intelligence-novo-plunges-on-obesity-shot-podcast",{"id":213,"title":214,"source":215,"logo":67,"time":107},469241,"Novo Nordisk slumps further on weight loss drugs in fight with Eli Lilly","https://www.axios.com/2026/02/23/ozempic-novo-nordisk-eli-lilly-zepbound",{"id":217,"title":218,"source":219,"logo":33,"time":107},469042,"Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial","https://www.clinicaltrialsarena.com/news/novo-nordisks-cagrisema-bested-by-lillys-zepbound-in-head-to-head-trial/",{"id":221,"title":222,"source":223,"logo":59,"time":107},469041,"Europe bulletin: Novo Nordisk’s crash, IQM’s quantum leap, French crisis","https://invezz.com/news/2026/02/23/europe-bulletin-novo-nordisks-crash-iqms-quantum-leap-french-crisis/",{"id":225,"title":226,"source":227,"logo":71,"time":107},469040,"Novo’s Latest Obesity Flop Prompts Investors to Call for a Pivot","https://www.bloomberg.com/news/articles/2026-02-23/novo-s-latest-obesity-flop-prompts-investors-to-call-for-a-pivot",{"id":229,"title":230,"source":231,"logo":42,"time":107},467949,"Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial","https://www.cnbc.com/2026/02/23/novo-nordisk-stock-cagrisema-trial-fails-weight-loss.html",{"id":233,"title":234,"source":235,"logo":64,"time":107},467946,"Novo Nordisk: REDEFINE 4 Misses The Mark (NYSE:NVO)","https://seekingalpha.com/article/4873460-novo-nordisk-redefine-4-misses-the-mark",{"id":237,"title":238,"source":239,"logo":61,"time":107},466338,"Danish Drugmaker’s Weight Loss Medication Underperforms Against Competitor","https://www.finedayradio.com/news/tv-delmarva-channel-33/danish-drugmakers-weight-loss-medication-underperforms-against-competitor/",{"id":241,"title":242,"source":243,"logo":48,"time":107},467944,"Eli Lilly Surges as Novo Nordisk’s \"CagriSema\" Stumbles in High-Stakes Obesity Head-to-Head","https://markets.financialcontent.com/stocks/article/marketminute-2026-2-23-eli-lilly-surges-as-novo-nordisks-cagrisema-stumbles-in-high-stakes-obesity-head-to-head",{"id":245,"title":246,"source":247,"logo":58,"time":107},466339,"Novo Nordisk falls behind Lilly in obesity drug race","https://news.az/news/novo-nordisk-falls-behind-lilly-in-obesity-drug-race",{"id":249,"title":250,"source":251,"logo":57,"time":107},467945,"CagriSema Demonstrates Weight Loss, Fails to Achieve Primary Endpoint Compared to Tirzepatide","https://www.hcplive.com/view/cagrisema-demonstrates-weight-loss-fails-to-achieve-primary-endpoint-compared-to-tirzepatide",{"id":253,"title":254,"source":255,"logo":5,"time":107},466336,"Novo Nordisk shares plunge after obesity drug falls short of rival in trial","https://www.investing.com/news/stock-market-news/novo-nordisk-shares-plunge-after-obesity-drug-falls-short-of-rival-in-trial-4517946",{"id":257,"title":258,"source":259,"logo":44,"time":107},467942,"Danish Drugmaker’s Weight-Loss Drug Falls Short Against Rival in Clinical Trial","https://www.finedayradio.com/news/tv-delmarva-channel-33/danish-drugmakers-weight-loss-drug-falls-short-against-rival-in-clinical-trial/",{"id":261,"title":262,"source":263,"logo":24,"time":107},466337,"Novo Nordisk’s next-gen obesity drug stumbles in comparison study","https://www.statnews.com/2026/02/23/novo-nordisk-cagrisema-fail-comparison-trial-zepbound-eli-lilly-obesity/",{"id":265,"title":266,"source":267,"logo":5,"time":107},467943,"NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm","https://www.businesswire.com/news/home/20260223062589/en/NVO-Investors-Have-Opportunity-to-Join-Novo-Nordisk-AS-Fraud-Investigation-with-the-Schall-Law-Firm",{"id":269,"title":270,"source":271,"logo":74,"time":107},466334,"Why Is Novo Nordisk Stock Down 13% Premarket? Trial Fails to Match Eli Lilly","https://tokenist.com/why-is-novo-nordisk-stock-down-13-premarket-trial-fails-to-match-eli-lilly/",{"id":273,"title":274,"source":275,"logo":68,"time":107},467940,"Novo Nordisk’s New Weight Loss Shot Loses To Rival Eli Lilly In Clinical Trial—Stock Plummets","https://www.forbes.com/sites/martinadilicosa/2026/02/23/novo-nordisks-new-weight-loss-shot-loses-to-rival-eli-lilly-in-clinical-trial-stock-plummets/",{"id":277,"title":278,"source":279,"logo":43,"time":107},466335,"Novo Nordisk Stock Hits 52-Week Low After Weight-Loss Drug Falls Short Against Eli Lilly's","https://www.benzinga.com/trading-ideas/movers/26/02/50773610/novo-nordisk-stock-hits-52-week-low-after-weight-loss-drug-falls-short-against-eli-lillys",{"id":281,"title":110,"source":282,"logo":35,"time":107},467941,"https://www.fool.com/investing/2026/02/23/why-novo-nordisk-stock-just-crashed/",{"id":284,"title":146,"source":285,"logo":20,"time":107},466343,"https://www.marketwatch.com/story/novo-nordisk-pitted-a-new-weight-loss-drug-against-eli-lilly-and-lost-5652d079?gaa_at=eafs&gaa_n=AWEtsqeezl9hHjApMDZs4sdv5C09U2CFQ73whjJx5Y7DwBE03v6t1N2jYhFU&gaa_ts=699c46de&gaa_sig=CNBGJD1HhAFxq9rLR-d3t-CdsKXQCZVoWktAAorGBO9cf7jMDE2gf35tnWbQ6gBaquvspQxgR-2UrP8w7u24wA%3D%3D",{"id":287,"title":288,"source":289,"logo":69,"time":107},466344,"Novo Nordisk shares drop after poor trial results for new obesity drug","https://www.ft.com/content/979a4c4b-47f9-4b9f-894a-8ed7385c0b6a",{"id":291,"title":292,"source":293,"logo":27,"time":107},466341,"Novo Nordisk stock tumbles as next-gen obesity shot underperforms Lilly’s tirzepatide (NVO:NYSE)","https://seekingalpha.com/news/4555038-novo-nordisk-stock-tumbles-as-next-gen-obesity-shot-underperforms-lillys-tirzepatide",{"id":295,"title":138,"source":296,"logo":49,"time":107},466342,"https://ca.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-101120125.html",{"id":298,"title":299,"source":300,"logo":28,"time":107},466340,"Novo Nordisk’s obesity drug CagriSema falls short against Eli Lilly’s in trial By Reuters","https://www.investing.com/news/stock-market-news/novo-nordisks-obesity-drug-cagrisema-falls-short-against-eli-lillys-in-trial-4517952",{"id":302,"title":118,"source":303,"logo":5,"time":107},469051,"https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",{"id":305,"title":306,"source":307,"logo":5,"time":107},469050,"Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why","https://www.investopedia.com/novo-nordisk-stock-tumbles-monday-to-its-lowest-point-in-nearly-5-years-here-is-why-nvo-11911674",{"id":309,"title":310,"source":311,"logo":14,"time":107},466349,"Novo Nordisk's obesity drug falls short against Eli Lilly's in trial","https://www.globalbankingandfinance.com/novo-nordisks-obesity-drug-falls-short-against-eli-lillys/",{"id":313,"title":314,"source":315,"logo":45,"time":107},466347,"Eli Lilly beats Novo Nordisk's weight-loss hopes in direct comparison","https://medwatch.com/News/Pharma___Biotech/article19043985.ece",{"id":317,"title":318,"source":319,"logo":50,"time":107},466348,"Novo Nordisk falls 10% on obesity drug trial results","https://breakingthenews.net/Article/Novo-Nordisk-falls-10-on-obesity-drug-trial-results/65723805",{"id":321,"title":126,"source":322,"logo":72,"time":107},466345,"https://www.aastocks.com/en/usq/news/comment.aspx?source=AAFN&id=NOW.1504226&catg=1",{"id":324,"title":325,"source":326,"logo":73,"time":107},466346,"Novo-Nordisk A/S's stock price fell nearly 11% as the weight loss effect of its next-generation drug CagriSema was inferior to Eli Lilly and Co's flagship product.","https://news.futunn.com/en/post/69096937/novo-nordisk-a-s-s-stock-price-fell-nearly-11",{"id":328,"title":329,"source":330,"logo":65,"time":107},466233,"Novo Nordisk's CagriSema Underperforms: A Blow to Obesity Drug Market Dominance","https://www.devdiscourse.com/article/health/3814592-novo-nordisks-cagrisema-underperforms-a-blow-to-obesity-drug-market-dominance",{"id":332,"title":333,"source":334,"logo":37,"time":107},466234,"Novo Nordisk slump wipes out last Wegovy-era gains after trial setback","https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-slump-wipes-out-last-wegovy-era-gains-after-trial-setback-2026-02-23/",{"id":336,"title":337,"source":338,"logo":60,"time":107},466231,"Novo Nordisk slump wipes out last Wegovy-era gains after trial setback By Reuters","https://www.investing.com/news/stock-market-news/novo-nordisk-slump-wipes-out-last-wegovyera-gains-after-trial-setback-4518255",{"id":340,"title":333,"source":341,"logo":36,"time":107},466232,"https://www.globalbankingandfinance.com/novo-nordisk-slump-wipes-out-last-wegovy-era-gains-trial/",{"id":343,"title":344,"source":345,"logo":22,"time":107},467928,"Watch Novo Nordisk CSO on New Obesity Shot Results, Drug Pipeline","https://www.bloomberg.com/news/videos/2026-02-23/novo-nordisk-cso-on-new-obesity-shot-and-pipeline-video",{"id":347,"title":348,"source":349,"logo":16,"time":107},467929,"Novo's CagriSema fails to match Lilly's Zepbound in key obesity trial","https://firstwordpharma.com/story/7112611",{"id":351,"title":352,"source":353,"logo":52,"time":107},467926,"Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price","https://www.fiercebiotech.com/biotech/novos-cagrisema-loses-phase-3-battle-mounjaro-knocking-15-share-price",{"id":355,"title":356,"source":357,"logo":70,"time":107},467927,"Head-to-head trial dents Novo Nordisk's obesity hopes","https://pharmaphorum.com/news/head-head-trial-dents-novo-nordisks-obesity-hopes",{"id":359,"title":360,"source":361,"logo":31,"time":107},467924,"\"Major setback\": Analysts and investors agree on new Novo Nordisk downturn in slimming drug race","https://medwatch.com/News/Pharma___Biotech/article19045064.ece",{"id":363,"title":364,"source":365,"logo":5,"time":107},467925,"Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide","https://www.ndtv.com/health/novo-nordisks-cagrisema-delivers-23-weight-loss-in-trial-but-still-trails-eli-lillys-tirzepatide-11125328",{"id":367,"title":368,"source":369,"logo":51,"time":107},466239,"Novo stock drops 15% as obesity drug falls short in key trial","https://invezz.com/au/news/2026/02/23/novo-stock-drops-15percent-as-obesity-drug-falls-short-in-key-trial/",{"id":371,"title":158,"source":372,"logo":53,"time":107},466237,"https://www.barrons.com/articles/novo-nordisk-stock-eli-lilly-weight-loss-8715ba80?mod=barronsgooglenews&gaa_at=eafs&gaa_n=AWEtsqca1DOHgFWfQjLnIi7vYN5anlhAMexIAEYU5cATAsbzW_jXmcVyz6DX&gaa_ts=699c46de&gaa_sig=vxDRwqpQCJ8dVjD5LZVMmWI1fxPTfHzz79JXbv2nNlZQiqVWbeIjlDkD-wo1E7fVvj5o7kH_Bl7DSbtsOx54qA%3D%3D",{"id":374,"title":375,"source":376,"logo":66,"time":107},466238,"NOVO_B: CagriSema missed non-inferiority to Tirzepatide in REDEFINE 4, with 23% vs 25.5% weight loss","https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2909471:0-novo_b-cagrisema-missed-non-inferiority-to-tirzepatide-in-redefine-4-with-23-vs-25-5-weight-loss/",{"id":378,"title":254,"source":379,"logo":5,"time":107},466235,"https://ca.investing.com/news/stock-market-news/novo-nordisk-shares-plunge-after-obesity-drug-falls-short-of-rival-in-trial-4471108",{"id":381,"title":382,"source":383,"logo":18,"time":107},466236,"Novo Nordisk’s obesity drug CagriSema falls short against Eli Lilly’s in trial","https://whtc.com/2026/02/23/novo-nordisks-obesity-drug-cagrisema-falls-short-against-eli-lillys-in-trial/",{"id":385,"title":386,"source":387,"logo":55,"time":107},466244,"Novo Nordisk's CEO says still 'incredibly optimistic' about CagriSema","https://www.marketscreener.com/news/novo-nordisk-s-ceo-says-still-incredibly-optimistic-about-cagrisema-ce7e5dd2df8eff25",{"id":389,"title":390,"source":391,"logo":38,"time":107},469039,"Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin","https://www.investors.com/news/technology/novo-nordisk-dives-next-gen-obesity-drug-fails-to-match-eli-lilly-zepbound/",{"id":393,"title":394,"source":395,"logo":12,"time":107},466245,"Novo Nordisk (NVO) Shares Drop After CagriSema Trial Results","https://www.gurufocus.com/news/8641100/novo-nordisk-nvo-shares-drop-after-cagrisema-trial-results",{"id":397,"title":398,"source":399,"logo":5,"time":107},469038,"Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved","https://uk.finance.yahoo.com/news/novo-nordisk-cagrisema-demonstrated-23-093300508.html",{"id":401,"title":402,"source":403,"logo":46,"time":107},466242,"Novo Nordisk's Cagrisema: A Game-Changer in Weight Loss","https://www.devdiscourse.com/article/health/3814535-novo-nordisks-cagrisema-a-game-changer-in-weight-loss",{"id":405,"title":406,"source":407,"logo":20,"time":107},469037,"Novo Nordisk’s stock slips to four-year low after its next-gen weight-loss drug lost to Lilly’s in Phase 3 trial","https://www.marketwatch.com/story/novo-nordisk-pitted-a-new-weight-loss-drug-against-eli-lilly-and-lost-5652d079?gaa_at=eafs&gaa_n=AWEtsqex5YgcBzGyazOb9-uNrs2_eJbUzyZSExvLFwyWymFHQadgWFrL-5Ld&gaa_ts=699cb690&gaa_sig=-PpGxnKN0w87Nc5-gJjZAaYyhzNzjnzmv6Gqmm1uF_g0DiiuRgSLZeCdxQev8dnsLG2erzrM-hXZhXgddMz1Lw%3D%3D",{"id":409,"title":410,"source":411,"logo":21,"time":107},466243,"Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Rival in Trial","https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?gaa_at=eafs&gaa_n=AWEtsqe2Stu8hQG5l-r17Flugi9IeWMYm2Cw97mDOfhsd0tULTN7XnJNlqxT&gaa_ts=699c46de&gaa_sig=evZYF_vob3IVqdVjqoEGdFHNbjSZ4OfAQpeHt1qmt73w_5mmKJkdwgPRIWoQBQhmoNiSdSJigbO9lt7vzZ64RQ%3D%3D",{"id":413,"title":414,"source":415,"logo":56,"time":107},469036,"Watch Novo Next-Generation Obesity Shot Falls Short of Lilly Rival","https://www.bloomberg.com/news/videos/2026-02-23/novo-new-obesity-shot-falls-short-of-lilly-rival-video",{"id":417,"title":418,"source":419,"logo":10,"time":107},466240,"Novo Nordisk vs. Eli Lilly: The Billion-Dollar Drug War","https://privatetherapyclinics.co.uk/news/novo-nordisk-vs-eli-lilly-the-billion-dollar-drug-war/",{"id":421,"title":422,"source":423,"logo":15,"time":107},469035,"OMX Copenhagen dips 6% as Novo Nordisk sinks","https://breakingthenews.net/Article/OMX-Copenhagen-dips-6-as-Novo-Nordisk-sinks/65724862",{"id":425,"title":426,"source":427,"logo":23,"time":107},466241,"Novo Nordisk shares fall as Lilly stock climbs","https://news.az/news/novo-nordisk-shares-fall-as-lilly-stock-climbs","#a95a68ff","#a95a684d",1771983077071]